 |
|
Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
Seung-Hoon Lee, Sang Won Jeon, Cheolmin Shin, Chi-Un Pae, Ashwin A. Patkar, Prakash S. Masand, Hyonggin An, Changsu Han
Psychiatry Investig. 2022;19(4):268-280. Published online 2022 Apr 22 DOI: https://doi.org/10.30773/pi.2021.0368
|
|
The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature
Francesco Weiss, Bruno Pacciardi, Giulia D’Alessandro, Valerio Caruso, Icro Maremmani, Stefano Pini, Giulio Perugi
Journal of Clinical Medicine.2024; 13(2): 531. CrossRef An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
N Simple Santi, Sashi Bhusan Biswal, Birendra Narayan Naik, Jyoti Prakash Sahoo, Bhabagrahi Rath
Cureus.2023;[Epub] CrossRef Repercusión de vortioxetina sobre la función sexual frente a otros antidepresivos
F. Sánchez-Sánchez, B. Ponce-Buj, A.L. Montejo-González, Y. Sipán-Sarrión, A. Gimeno-Marqués, A. Merino-Gámez
Medicina de Familia. SEMERGEN.2023; 49(7): 101997. CrossRef Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper
Gaia Sampogna, Filippo Caraci, Claudia Carmassi, Bernardo Dell’Osso, Silvia Ferrari, Giovanni Martinotti, Gabriele Sani, Gianluca Serafini, Maria Salvina Signorelli, Andrea Fiorillo
Expert Opinion on Pharmacotherapy.2023; 24(14): 1511. CrossRef Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism—In Vitro Study
Matej Ľupták, Zdeněk Fišar, Jana Hroudová
International Journal of Molecular Sciences.2022; 23(22): 13824. CrossRef
|